MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
DGX - Quest Diagnostics, Inc.
$145.36
-1.49(-1.01%)8:02:40 PM 10/21/2021
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. As of 2020 the company had approximately 47,000 employees, and generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19 and employment and court ordered drug testing.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap17.8B
PE Ratio8.7
PEG Ratio-1.4
P/B2.5
P/S (ttm)1.5
Earning Growth (QoQ)374%
Revenue Growth (QoQ)
Short %9%
Held by Institutions %93%
1 Day Vol Adjusted Return-0.9
1 Month Vol Adjusted Return-4.1
3 Month Vol Adjusted Return4.3
6 Month Vol Adjusted Return10.8
20 Days SMA Price ZScore0.4
50 Days SMA Price ZScore-0.8
12 -26 Days PPO-1.0
1 Month Average Short Volume Ratio47.0
1 Day Volume Change ZScore1.9
1 Month Daily Vol1.2
Related Topics
Peers

Stock news

    10/21/2021DGX
    Supporting Employees' Emotional Health During the Pandemic

    When it comes to the well-being of our employees, mental and emotional health are just as important as physical wellness. With the increased prevalence of mental health issues in connection with CO...

    10/21/2021DGX
    Quest Diagnostics Inc (DGX) Q3 2021 Earnings Call Transcript

    The entire contents of the call, including the presentation and question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. Now, I would like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics.

    10/21/2021DGX
    Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up

    Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.

    10/21/2021DGX
    Quest Raises FY21 Outlook Again On Strong COVID-19 Volumes In Q3

    View more earnings on DGXSee more from BenzingaClick here for options trades from BenzingaDanaher's Q3 Earnings Beats Street EstimatesTenet Achieves Quarterly Operating Income Of B, Raises FY21 Outlook© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    10/21/2021DGX
    Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates

    Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    10/21/2021DGX
    UPDATE 3-Quest Diagnostics sees slowdown in COVID-19 testing in fourth quarter

    Quest Diagnostics Inc on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a recovery in its core testing business will likely cushion the blow. Shares of the U.S. laboratory reversed course and fell 3.5% to $141.75 in early trading after it said it expects to record about 50,000 molecular tests per day in the fourth quarter.

    10/21/2021DGX
    Quest Diagnostics net income falls; hikes 2021 outlook

    Quest Diagnostics Inc. said Thursday its third-quarter net income fell to $505 million, or $4.02 a share, from $568 million, or $4.14 a share in the year-ago quarter. Adjusted earnings fell to $3.96 a share from $4.31 a share. Revenue at the medical testing company dropped to $2.774 billion from $2.786 billion. Analysts expected the company to earn $2.88 a share on revenue of $2.452 billion, according to a FactSet survey. Quest Diagnostics said it's lifting its 2021 profit target to a range of $

    10/21/2021DGX
    Quest Diagnostics sees slowdown in COVID-19 testing in fourth quarter

    (Reuters) -Quest Diagnostics Inc on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a recovery in its core testing business will likely cushion the blow. Shares of the U.S. laboratory reversed course and fell 3.5% to $141.75 in early trading after it said it expects to record about 50,000 molecular tests per day in the fourth quarter.